Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03988166
Other study ID # ST2955
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date May 20, 2020
Est. completion date February 22, 2021

Study information

Verified date October 2021
Source Vascular Solutions LLC
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this study is to evaluate angiographic confirmation of placement of any guidewire beyond the CTO, in the true vessel lumen, in patients undergoing CTO percutaneous coronary intervention (PCI) in which at least one Teleflex guidewire and at least one Turnpike catheter are used.


Description:

A prospective, multicenter, single-arm, intent-to-treat, literature-controlled clinical study. The study will be conducted in up to 15 investigational sites in the U.S. This study will enroll up to 150 patients to provide adequate powering for hypothesis testing and an evaluable sample size of at least 135 patients. The population for this study is participants with signs and/or symptoms considered typical of ischemic heart disease attributed to a de novo CTO in a native coronary artery who are suitable candidates for a percutaneous revascularization. Study devices include the GuideLiner® V3 catheter, TrapLiner® catheter, Turnpike® catheter, and a series of five coronary guidewires (SpectreTM guidewire, R350TM guidewire, RaiderTM guidewire, WarriorTM guidewire, and BanditTM guidewire). All study devices are currently 510(k) cleared for non-CTO indications. - GuideLiner catheters are intended to be used in conjunction with guide catheters to access discrete regions of the coronary and/or peripheral vasculature, to facilitate placement of interventional devices, and to assist in crossing de novo chronic total occlusions (CTO). - The TrapLiner catheter is intended for use in conjunction with guide catheters to access discrete regions of the coronary and/or peripheral vasculature, to facilitate placement of interventional devices, to facilitate the exchange of an interventional device while maintaining the position of a guidewire within the vasculature, and to assist in crossing de novo chronic total occlusions (CTO). - The Turnpike catheters are intended to be used to access discrete regions of the coronary and/or peripheral vasculature. They may be used to facilitate placement and exchange of guidewires, to subselectively infuse/deliver diagnostic and therapeutic agents, and to assist in crossing de novo coronary chronic total occlusions (CTO). The Teleflex guidewires are intended for use in percutaneous procedures to introduce and position catheters and other interventional devices within the coronary and peripheral vasculature, including use in crossing or assisting in crossing de novo coronary chronic total occlusions (CTO).


Recruitment information / eligibility

Status Completed
Enrollment 150
Est. completion date February 22, 2021
Est. primary completion date February 22, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Participants must meet all of the following inclusion criteria: General inclusion criteria 1. At least 18 years of age at the time of consent 2. Experiencing clinical symptoms considered suggestive of ischemic heart disease (e.g., chest pain or discomfort, heart failure) or has evidence of myocardial ischemia (e.g., abnormal functional study) attributed to the CTO target vessel and is scheduled for clinically indicated percutaneous revascularization 3. Participant is eligible and consents to undergo PCI procedure 4. Acceptable candidate for percutaneous transluminal coronary angioplasty (PTCA), stenting, and emergency coronary artery bypass grafting (CABG) 5. Willing and able to sign a study Informed Consent Form (ICF) approved by a local or central Institutional Review Board (IRB) 6. Female participants of childbearing potential must have a negative pregnancy test per standard of care for PCI and be practicing contraception Angiographic inclusion criteria 7. A minimum of one de novo lesion with at least one target segment in a native coronary vessel meeting the definition of CTO (any non-acute total coronary occlusion fulfilling the angiographic characteristics consistent with high-grade native coronary stenosis (Thrombolysis in Myocardial Infarction (TIMI) score of 0 or 1) and estimated to be in duration of = 3 months by clinical history and/or comparison with antecedent angiogram or electrocardiogram) Exclusion Criteria: Participants must not meet any of the following exclusion criteria: General exclusion criteria 1. History of allergy to iodinated contrast that cannot be effectively managed medically 2. Evidence of acute myocardial infarction (MI) within 72 hours prior to the intended treatment defined as creatine kinase-muscle brain subunits (CK-MB) greater than 3 times the upper limit of normal (ULN) 3. Previous coronary interventional procedure of any kind within 30 days prior to the procedure 4. Any contraindication to cardiac catheterization or to any of the standard concomitant therapies used during routine cardiac catheterization and PCI (e.g., aspirin, clopidogrel, unfractionated heparin) 5. Target lesion requires treatment with another device, after successful crossing with a study device, other than PTCA devices prior to stent placement 6. Atherectomy procedure is planned for the target lesion 7. Known history of clinically significant abnormal laboratory findings = 14 days prior to enrollment, including: - Neutropenia (<1000 neutrophils/mm^3) - Thrombocytopenia (<100,000 platelets/mm^3) - Aspartate aminotransferase (AST), alanine transaminase (ALT), alkaline phosphatase, or bilirubin > 1.5 × ULN - Serum creatinine >2.0 mg/dL 8. Evidence of current clinical instability including the following: - Sustained systolic blood pressure <100 mmHg or cardiogenic shock - Acute pulmonary edema or severe congestive heart failure (CHF). Severe CHF is defined as New York Heart Association (NYHA) Class IV - Suspected acute myocarditis, pericarditis, endocarditis, or cardiac tamponade - Suspected dissecting aortic aneurysm - Hemodynamically significant valvular heart disease, hypertrophic cardiomyopathy, restrictive cardiomyopathy, or congenital heart disease 9. History of stroke or transient ischemic attack within 6 months prior to procedure 10. Active peptic ulcer or upper gastrointestinal bleeding within 6 months prior to procedure 11. History of bleeding diathesis or coagulopathy or refusal of blood transfusions 12. Other pathology such as cancer, known mental illness, etc., which might, in the opinion of the Investigator, put the patient at risk or confound the results of the study 13. Unable or unwilling to comply with the protocol 14. Currently participating in an investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the current study endpoints; or requires coronary angiography, intravascular ultrasound, or other coronary artery imaging procedures Angiographic exclusion criteria 15. Occlusion involves segment within previous stent ("in-stent occlusions") 16. Extensive lesion-related thrombus (TIMI thrombus grade 3 or 4) 17. Previous stenting (drug-eluting or bare metal) in the target vessel unless the following conditions are met: - It has been at least 9 months since the previous stenting - Target lesion is =15 mm away from the previously placed stent - Previously stented segment (stent plus 5 mm on either side) has no more than 40 percent diameter stenosis, based on visual estimate 18. Target vessel has other lesions proximal to the total occlusion identified with > 75 percent diameter stenosis based on visual estimate; exception: planned stenting of a lesion proximal to the target lesion that can be covered by a single stent (i.e., tandem lesions) is acceptable

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Chronic Total Occlusion Revascularization
Teleflex's series of study guidewires and catheters will be used to facilitate the safe and effective crossing of de novo CTOs and placement of conventional guidewires beyond the lesion via either a true lumen or subintimal pathway.
Device:
GuideLiner® V3 catheter, TrapLiner® catheter, Turnpike® catheter
GuideLiner® V3 catheter, TrapLiner® catheter, Turnpike® catheter

Locations

Country Name City State
United States Emory University Atlanta Georgia
United States Piedmont Heart Institute Atlanta Georgia
United States Beth Israel Deaconess Medical Center Boston Massachusetts
United States Brigham and Women's Hospital Boston Massachusetts
United States Massachusetts General Hospital Boston Massachusetts
United States The Christ Hospital Cincinnati Ohio
United States Missouri Cardiovascular Specialists Columbia Missouri
United States Henry Ford Hospital Detroit Michigan
United States Minneapolis Heart Institute Foundation Minneapolis Minnesota
United States Columbia University Medical Center New York New York
United States NYU Langone Health New York New York
United States University of Washington Seattle Washington
United States Torrance Memorial Medical Center Torrance California

Sponsors (3)

Lead Sponsor Collaborator
Vascular Solutions LLC Bright Research Partners, Teleflex

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With Procedure Success Defined as angiographic visualization of any guidewire in a position either distal or proximal to the occlusion depending on the route of access and the absence of in-hospital major adverse cardiac events (MACE).
• MACE defined as any serious adverse experience that includes cardiac death, target lesion revascularization, or post-procedural myocardial infarction (MI) (Q-wave or non-Q-wave, with creatine kinase (CK) with Muscle (M)-Brain (B) subunits > 3 ULN).
Through Discharge up to 24 hours post-procedure
Secondary Number of Participants With Successful Recanalization. Defined as angiographic confirmation of crossing the chronic total occlusion and restoring blood flow to the affected area. Through Procedure, up to 4 hours
Secondary Number of Participants With In-hospital MACE. Defined as any serious adverse experience that includes cardiac death, target lesion revascularization, or post-procedural MI (Q-wave or non-Q-wave, with CK-MB > 3 ULN). The components of MACE will also be reported separately. Through Discharge up to 24 hours
Secondary Number of Participants With Clinically Significant Perforation. Defined as any perforation resulting in hemodynamic instability and/or requiring intervention including pericardiocentesis, embolization, prolonged balloon occlusion, stent graft, or comparable therapy. Through Procedure up to 4 hours
Secondary Number of Participants With Procedural Success According to Crossing Technique. Procedural success is defined as angiographic visualization of any guidewire in a position either distal or proximal to the occlusion depending on the route of access and the absence of in-hospital major adverse cardiac events (MACE). Through Procedure up to 4 hours post-procedure
Secondary Number of Participants With Technical Success. Defined as successful guidewire recanalization is applicable to investigational devices as at least one investigational guidewire must be used in every procedure. Through Procedure up to 4 hours post-procedure
See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Recruiting NCT06002932 - Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions. N/A
Active, not recruiting NCT04562805 - Infinity-Swedeheart Registry Based Randomized Clinical Trial (R-RCT) N/A
Recruiting NCT05292079 - CAPTURER PMCF Study ( rEPIC04D )
Recruiting NCT05292014 - ANGIOLITE PMCF Study ( rEPIC04F )
Recruiting NCT05292092 - Essential Pro PMCF Study ( rEPIC04E )
Recruiting NCT05292118 - Navitian PMCF Study ( rEPIC04C )
Completed NCT05292105 - NC Xperience PMCF Study( rEPIC04B)
Completed NCT03076801 - Does Choral Singing Help imprOve Stress in Patients With Ischemic HeaRt Disease? N/A
Not yet recruiting NCT04153383 - Milrinone on Cardiac Performance During Off-pump Coronary Artery Bypass Surgery
Recruiting NCT02729064 - Intraoperative Nasal Insulin Effect on Plasma and CSF Insulin Concentration and Blood Glucose Phase 1
Recruiting NCT02982434 - The New Pharmaceutical Composition Containing Botulinum Toxin to Treat Atrial Fibrillation Phase 2
Completed NCT02468401 - Prevention of Contrast Induced Nephropathy in Patients With Advanced Renal Dysfunction Undergoing Coronary Interventions N/A
Completed NCT02759406 - Evaluation of the Palmaz Mach-5 Grooved Bare Metal Coronary Stent System Versus the Palmaz Bare Metal Coronary Stent System in Patients With Symptomatic Ischemic Heart Disease: A Safety and Performance Study N/A
Recruiting NCT01681381 - Evaluate Safety And Effectiveness Of The Tivoli® DES and The Firebird2® DES For Treatment Coronary Revascularization N/A
Completed NCT01699802 - Influence of Inhaled Anaesthetics on Rebreathing of Carbon Dioxide When Using an Anaesthesia Gas Reflector (AnaConDa) N/A
Completed NCT01604213 - Effects of Vildagliptin/Metformin Combination on Markers of Atherosclerosis, Thrombosis, and Inflammation in Diabetics With Coronary Artery Disease Phase 4
Completed NCT01724567 - Copenhagen Study of Obese Patients With Ischemic Heart Disease Undergoing Low Energy Diet or Interval Training N/A
Completed NCT01334268 - RESOLUTE China RCT N/A
Completed NCT02159235 - Heavy Metals, Angiogenesis Factors and Osteopontin in Coronary Artery Disease (CAD) N/A